View Post

Extended Letrozole Reduced Recurrence Risk in Postmenopausal Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Mike Bassett From: medpagetoday.com 5 years of the aromatase inhibitor improved disease-free survival vs 2-3 years Five years of extended treatment with the aromatase inhibitor letrozole significantly improved disease-free survival (DFS) compared with the standard duration of 2 to 3 years in postmenopausal patients with breast cancer who had already received 2 to 3 years of tamoxifen, according to …

View Post

What You Need to Know About Breast Cancer Chemotherapy Pills

In In The News by Barbara Jacoby

From: healthline.com People commonly associate chemotherapy with intravenous (IV) cancer drugs in a hospital or doctor’s office. This has been the traditional nonsurgical method of treating cancer. Due to recent advances in cancer treatments, oral chemotherapy pills have become more widely used for many types of cancer. There are a few that are approved for breast cancer, including capecitabine (Xeloda), …

View Post

An Estrogen Receptor that Promotes Cancer also Causes Drug Resistance

In Clinical Studies News by Barbara Jacoby

By: Laura Kurtzman From: ucsf.edu UCSF Researchers Discover New Role for Erα as an RNA-Binding Protein Cancer cells proliferate despite a myriad of stresses – from oxygen deprivation to chemotherapy – that would kill any ordinary cell. Now, researchers at UC San Francisco have gained insight into how they may be doing this through the downstream activity of a powerful …

View Post

Value-Based Decision-Making in Metastatic Breast Cancer

In In The News by Barbara Jacoby

From: managedhealthcareexecutive.com In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of …

View Post

Blood enzyme activity level may indicate which breast cancers are slow growing

In Clinical Studies News by Barbara Jacoby

By: SWOG Cancer Research Network From: medicalxpress.com Researchers with the SWOG Cancer Research Network have found that patients with metastatic hormone receptor-positive breast cancer who have low activity levels of the enzyme sTK1 in their blood serum at the start of anti-estrogen treatment live longer and go longer without their disease progressing than patients with high levels. The results suggest …

View Post

Study identifies possible link between antibiotic use and breast cancer growth

In In The News by Barbara Jacoby

By: Darcy Jimenez From: pharmaceutical-technology.com New research has uncovered a possible link between antibiotic use and the speed of breast cancer growth in mice, and identified an immune cell that could be used to reverse the effect. The study, funded by Breast Cancer Now and conducted by scientists from the Quadram Institute and the University of East Anglia (UEA), involved …

View Post

Microwave imaging could provide safer, more comfortable breast cancer screening

In Clinical Studies News by Barbara Jacoby

From: physicsworld.com Microwave breast imaging (MBI) represents a promising non-invasive technology for detection of breast tumours. It does not utilize ionizing radiation nor require breast compression, potentially offering a safer and more comfortable method for breast cancer screening. As of 2020, 10 MBI prototypes had been clinically tested. Researchers at Galway University Hospital and the National University of Ireland Galway …

View Post

IceCure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the ICE3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cance

In In The News by Barbara Jacoby

Source: IceCure Medical From: prnewswire.com IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that the first peer reviewed article “Cryoablation Without Excision for Low-Risk, Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial” was published in the …

View Post

HER2+ Breast Cancer: Key Takeaways From HER2CLIMB

In Clinical Studies News by Barbara Jacoby

By: Giuseppe Curigliano, MD, PhD From: onclive.com An overview of the latest data demonstrated by the HER2CLIMB study evaluating the efficacy and safety of tucatinib in combination with capecitabine and trastuzumab for patients with relapsed/refractory metastatic HER2-positive breast cancer. Giuseppe Curigliano, MD, PhD: Tucatinib is a highly selective HER2 [human epidermal growth factor receptor 2]–directed tyrosine kinase inhibitor. The specificity …